Fresenius Medical Care

DE0005785802

Fresenius Medical Care AG & Co. KGaA provides kidney dialysis services through a network of 3,994 outpatient dialysis centers, serving 345,096 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives. With a global headquarters in Bad Homburg vor der Höhe, Germany and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 45 production sites, the largest of which are in the U.S., Germany, and Japan.The company is 30% owned by Fresenius and, as of 2020, generates around 50% of the group’s revenue.The company is on the Best Employers List published by Forbes.

Fresenius Medical Care has been a target of short sellers for a while. The current short interest of 3.17% is roughly at the average of the last 12 months (1.34%). Recently, short selling has increased slightly.

History